Drug profile · INN
iptacopan hydrochloride
FABHALTA
iptacopan hydrochloride (FABHALTA) is a complement factor b inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — iptacopan hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
iptacopan hydrochloride (FABHALTA) is a complement factor b inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Complement factor B inhibitor
Primary target: Complement factor B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is iptacopan hydrochloride?
iptacopan hydrochloride (FABHALTA) is a complement factor b inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for iptacopan hydrochloride?
FABHALTA is a marketed brand name for iptacopan hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of iptacopan hydrochloride?
iptacopan hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.